WATCHLONGEVITY

Saturday, June 20, 2026

April - June 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Importance
62
Trust
80
Urgency
30
SAFETY · PRIMARY SOURCE

April - June 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)

The FDA found that GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro may cause intestinal blockages. The agency updated drug labels between late 2022 and mid-2023 to warn patients about this risk.

Analysis

FDA added intestinal blockage warnings to all GLP-1 drug labels. Patients on Ozempic, Wegovy, and Mounjaro need to know this risk is now official.

  • FDA updated GLP-1 drug labels between November 2022 and September 2023 to include ileus risk
  • Drugs affected include Mounjaro (tirzepatide), Ozempic, Wegovy, Rybelsus (all semaglutide), and others
  • The ileus warning was added to the 'Adverse Reactions' section of affected drug labeling
$NVO$LLY
semaglutidetirzepatideliraglutidedulaglutide
FDA Drug Approvals & Databases8d
Read
October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
DEVELOPING
Importance
72
Trust
70
Urgency
65
SAFETY · PRIMARY SOURCE

October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)

Analysis

FDA is reviewing a possible link between GLP-1 drugs and blindness (NAION). Ozempic, Wegovy, Mounjaro, and Zepbound are all on the list.

  • FDA flagged GLP-1 receptor agonists for non-arteritic anterior ischemic optic neuropathy (NAION)
  • Drugs named include Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound
  • FDA is evaluating the need for regulatory action as of March 6, 2025
$NVO$LLY
lixisenatideexenatidetirzepatidesemaglutide
FDA Drug Approvals & Databases8d
Read
January - March 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Importance
62
Trust
70
Urgency
30
SAFETY · PRIMARY SOURCE

January - March 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)

The FDA listed GLP-1 weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound as having a possible safety signal for a nerve problem called dysaesthesia (abnormal skin sensations). The agency is still studying whether the drugs caused these reports and whether label changes are needed.

Analysis

FDA flagged a nerve sensation problem linked to Ozempic, Wegovy, Mounjaro, and Zepbound. No label changes yet, but the agency is still deciding what to do.

  • FDA identified dysaesthesia as a potential safety signal for the full GLP-1 receptor agonist drug class
  • Named drugs include Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Byetta
  • As of June 21, 2024, FDA is evaluating the need for regulatory action — no label changes made yet
$NVO$LLY
semaglutidetirzepatideliraglutideexenatide
FDA Drug Approvals & Databases8d
Read
Importance
72
Trust
71
Urgency
30
SCIENCE

Q&A: Tirzepatide Outperforms Dulaglutide in Cardiorenal Outcomes, With Steven Nissen, MD - Patient Care Online

A doctor discusses how tirzepatide (a weight-loss and diabetes drug) works better than dulaglutide (another similar drug) at protecting the heart and kidneys. The comparison comes from recent trial data showing tirzepatide's benefits.

Analysis

Lilly's tirzepatide looks better than older Lilly drug dulaglutide for heart and kidney health. This gives doctors more reason to pick tirzepatide for patients with diabetes.

  • Tirzepatide beat dulaglutide on heart and kidney outcomes in a head-to-head comparison
  • Steven Nissen, MD discussed the trial data in a Q&A
  • Both drugs are made by Eli Lilly
$LLY
tirzepatidedulaglutide
Tirzepatide News2mo
Read